Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Diffuse midline glioma with an H3 K27M mutation: A comparison integrating the clinical, radiological, molecular features between adult and pediatric patients.

Jiang H, Yang K, Ren X, Cui Y, Li M, Lei Y, Lin S.

Neuro Oncol. 2019 Aug 24. pii: noz152. doi: 10.1093/neuonc/noz152. [Epub ahead of print]

PMID:
31504810
2.

Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.

Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, Puget S, Sainte-Rose C, Kramm CM, Jones C, Varlet P, Pfister SM, Grill J, Jones DTW, Debily MA.

Acta Neuropathol Commun. 2018 Nov 5;6(1):117. doi: 10.1186/s40478-018-0614-1.

3.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, K├╝hnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM.

Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.

4.

Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.

Chanchotisatien A, Pan J, Du Z, Qiu T, Yu J, Chu S.

World Neurosurg. 2019 Jul;127:266-268. doi: 10.1016/j.wneu.2019.04.054. Epub 2019 Apr 11.

PMID:
30981797
5.

Extending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin.

Gilbert AR, Zaky W, Gokden M, Fuller CE, Ocal E, Leeds NE, Fuller GN.

Pediatr Neurosurg. 2018;53(1):59-63. doi: 10.1159/000481513. Epub 2017 Nov 4.

PMID:
29131126
6.

Characteristics of H3 K27M-mutant gliomas in adults.

Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, Forest F, Rousselot-Denis C, Burel-Vandenbos F, Bourg V, Guyotat J, Fenouil T, Jouvet A, Honnorat J, Ducray F.

Neuro Oncol. 2017 Aug 1;19(8):1127-1134. doi: 10.1093/neuonc/now274.

7.

High frequency of H3 K27M mutations in adult midline gliomas.

Ebrahimi A, Skardelly M, Schuhmann MU, Ebinger M, Reuss D, Neumann M, Tabatabai G, Kohlhof-Meinecke P, Schittenhelm J.

J Cancer Res Clin Oncol. 2019 Apr;145(4):839-850. doi: 10.1007/s00432-018-02836-5. Epub 2019 Jan 4.

PMID:
30610375
8.

H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.

Kleinschmidt-DeMasters BK, Mulcahy Levy JM.

Clin Neuropathol. 2018 Mar/Apr;37 (2018)(2):53-63. doi: 10.5414/NP301085.

9.

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP.

J Neurooncol. 2019 Oct;145(1):97-105. doi: 10.1007/s11060-019-03271-3. Epub 2019 Aug 27.

PMID:
31456142
10.

[Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].

Li HN, Shan CG, Fan CZ, Cheng LN, Wu SG, Liu MT, Jiang GY, Li Z.

Zhonghua Bing Li Xue Za Zhi. 2019 Mar 8;48(3):192-198. doi: 10.3760/cma.j.issn.0529-5807.2019.03.005. Chinese.

PMID:
30831644
11.

Imaging characteristics of adult H3 K27M-mutant gliomas.

Qiu T, Chanchotisatien A, Qin Z, Wu J, Du Z, Zhang X, Gong F, Yao Z, Chu S.

J Neurosurg. 2019 Nov 15:1-9. doi: 10.3171/2019.9.JNS191920. [Epub ahead of print]

PMID:
31731269
12.

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.

Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M.

J Neurooncol. 2019 May;143(1):87-93. doi: 10.1007/s11060-019-03134-x. Epub 2019 Mar 12.

13.

Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.

Aboian MS, Tong E, Solomon DA, Kline C, Gautam A, Vardapetyan A, Tamrazi B, Li Y, Jordan CD, Felton E, Weinberg B, Braunstein S, Mueller S, Cha S.

AJNR Am J Neuroradiol. 2019 Nov;40(11):1804-1810. doi: 10.3174/ajnr.A6302. Epub 2019 Nov 6.

PMID:
31694820
14.

H3 K27M-mutant diffuse midline gliomas in different anatomical locations.

Wang L, Li Z, Zhang M, Piao Y, Chen L, Liang H, Wei Y, Hu Z, Zhao L, Teng L, Lu D.

Hum Pathol. 2018 Aug;78:89-96. doi: 10.1016/j.humpath.2018.04.015. Epub 2018 May 1.

PMID:
29727696
15.

Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System.

Yi S, Choi S, Shin DA, Kim DS, Choi J, Ha Y, Kim KN, Suh CO, Chang JH, Kim SH, Yoon DH.

Neurosurgery. 2019 May 1;84(5):1072-1081. doi: 10.1093/neuros/nyy150.

PMID:
29718432
16.

Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging.

Jung JS, Choi YS, Ahn SS, Yi S, Kim SH, Lee SK.

Neuroradiology. 2019 Mar;61(3):313-322. doi: 10.1007/s00234-019-02154-8. Epub 2019 Jan 20.

PMID:
30662997
17.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.

J Neurosurg Pediatr. 2019 Apr 5:1-7. doi: 10.3171/2019.2.PEDS18480. [Epub ahead of print]

PMID:
30952114
18.

A Rare High-Grade Glioma with a Histone H3 K27M Mutation in the Hypothalamus of an Adult Patient.

He P, Chen W, Qiu XX, Xi YB, Guan H, Xia J.

World Neurosurg. 2019 Aug;128:527-531. doi: 10.1016/j.wneu.2019.04.172. Epub 2019 Apr 29.

PMID:
31048046
19.

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL.

Nat Med. 2018 May;24(5):572-579. doi: 10.1038/s41591-018-0006-x. Epub 2018 Apr 16.

20.

Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.

Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM.

Oncotarget. 2018 Dec 14;9(98):37112-37124. doi: 10.18632/oncotarget.26430. eCollection 2018 Dec 14. Erratum in: Oncotarget. 2019 Apr 12;10(28):2788.

Supplemental Content

Support Center